Cytori Therapeutics (CYTX) Trading Down 6.2%

Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) dropped 6.2% during trading on Tuesday . The stock traded as low as $0.30 and last traded at $0.28. Approximately 791,240 shares were traded during trading, an increase of 2% from the average daily volume of 777,109 shares. The stock had previously closed at $0.30.

CYTX has been the subject of several recent research reports. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research lowered shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. analysts expect that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.

An institutional investor recently raised its position in Cytori Therapeutics stock. Sabby Management LLC lifted its holdings in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,626,807 shares of the biotechnology company’s stock after purchasing an additional 355,504 shares during the quarter. Sabby Management LLC owned approximately 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent SEC filing. 7.41% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Cytori Therapeutics (CYTX) Trading Down 6.2%” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/12/05/cytori-therapeutics-cytx-trading-down-6-2.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

What are top analysts saying about Cytori Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit